See feature article below: BioLife Solutions, Inc. (NASDAQ: BLFS)

Broad Street Alerts recent profiles and track record, 642% in verifiable potential gains for our members on 3 recent small cap alerts alone!

May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit over $4.15/share within 8 days for potential gains of 548% for our members.

May 23^rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.

May 26^th, 2016 (NASDAQ: CETX) opened at $2.00/share and hit $3.50/share within 10 days for potential gains of 74% for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report For: BioLife Solutions, Inc. (NASDAQ: BLFS)

Shares of BLFS are up 89% this morning on news the company has entered into a long term agreement to supply CryoStor clinical grade freeze media for cells and tissues with Kite Pharma. The company’s shares hit $3.00 per share in early morning trading on volume exceeding 10 million shares. The average daily volume for BLFS is 10 thousand shares.

 

BOTHELL, Wash., July 11, 2016 /PRNewswire/ — BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers (“BioLife” or the “Company”), today announced that it has entered into a ten year supply agreement with Kite Pharma, a leading developer of chimeric antigen receptor (CAR) and T cell receptor (TCR) products for various cancers.

The agreement provides for Kite’s supply of BioLife’s CryoStor clinical grade freeze media for cells and tissues, which is embedded in Kite’s manufacturing process for KTE-C19, a CAR T cell therapy currently in four clinical trials for various cancers.

Marc Better, Vice President, Product Sciences at Kite Pharma, noted, “Over the last several years we have worked to qualify and adopt CryoStor in our clinical manufacturing process. We are now securing long term supply continuity for this reagent as our cell therapy product candidate continues to progress through multiple clinical trials.”

Mike Rice, BioLife President & CEO, commented, “We are honored that Kite has adopted CryoStor in their production process for truly remarkable and potentially life-saving cellular therapies. We are committed to supporting Kite with great customer service and high quality products and look forward to the interim data readout from Kite’s first clinical trial later this year.”

About BioLife Solutions

BioLife Solutions develops, manufactures and markets biopreservation media products and smart shipping containers connected to a cloud hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.

 

 

 

DISCLAIMER

 

Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

 

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

 

 

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

 

 

 

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.

 

 

 

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

 

 

 

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.

 

 

 

Please Note: We do NOT accept free trading or restricted securities as payment for our services.

 

 

 

SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

Stock market

 

Hot small cap stocks

 

small cap stock picks

 

Biotech stocks

 

FDA approval stocks

 

FDA calendar

 

Trade stocks

 

Become a day trader

 

Day trade stocks for a living

 

PDUFA date set

 

micro cap stocks

 

Best stocks 2016

 

Hottest small cap stocks

 

Best stock picks

 

Who to follow for stock picks

 

Apple news stock picks

 

Stock picks on apple news

New York, NY- June 23rd, 2016- (Apple News) –  Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a biotechnology company, engages in the aquaculture and development of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating molecule used as an active pharmaceutical ingredient in various new immunotherapies. SBOT shares are up 19% at $3.89 with trading volume over four times the daily average. Read an analyst’s opinion in the report that follows. There is no cost or obligation to view the full report- https://broadstreetalerts.com/stellar/

 

 

About Broad Street Alerts

 

We make the connection between sophisticated investors and emerging growth small-cap companies. We are an issuer of reports written by chartered financial analysts (CFA’s) and or market experts who provide an assessment of the profiled company and have pledged to provide factual up to date information in their research. They include stocks traded in the NYSE and NASDAQ exchanges.

 

Safe Harbor Statement

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

 

Compliance Procedure

 

Content is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and research report. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

 

Contact: editor@BroadStreetAlerts.com

 

SOURCE: Broad Street Alerts

See feature article below: Stellar Biotechnologies, Inc. (NASDAQ: SBOT)

Broad Street Alerts recent profiles and track record, 642% in verifiable potential gains for our members on 3 recent small cap alerts alone!

May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit over $4.15/share within 8 days for potential gains of 548% for our members.

May 23^rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.

May 26^th, 2016 (NASDAQ: CETX) opened at $2.00/share and hit $3.50/share within 10 days for potential gains of 74% for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report For: Stellar Biotechnologies, Inc. (NASDAQ: SBOT)

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating molecule used as an active pharmaceutical ingredient in various new immunotherapies; and as an injectable product to assess immune response. SBOT shares are up 19% at $3.89 with trading volume over four times the daily average.

______________________

Interview of Maxim Groups Jason McCarthy by Streetwise’s Tracy Salcedo

Jason McCarthy: Given the current bear market—the correction we’ve seen over the last six months in the biotech markets—we believe the stock is artificially depressed, like most of biotech right now. The stock was closer to $7–8/share not long ago.

The value proposition revolves around what Stellar’s partners are doing. The company has key partnerships, including one with Neovacs SA (ALNEV:Alternext Paris), a French company working on systemic lupus. It also has a partner in OBI Pharma Inc. (4174:Taipei) in China, which is working in breast cancer. OBI recently presented promising data from a Phase 2b study demonstrating statistically significant improvements in progression-free survival and overall survival in women that generated immune responses from OBI’s keyhole limpet hemocyanin (KLH)-based vaccine. A Phase 3 study is now being planned. In addition, Stellar has undisclosed partners working in Alzheimer’s disease, as well as other undisclosed oncology and autoimmune indications.

“Stellar’s KLH is a part of what could be blockbuster vaccines.”
What drives biotech is data: data showing definitive proof of concept, data from a Phase 3 study that moves a therapy closer to a biologic license application, a new drug application filing or drug approval. When you see these successes from biotech companies, you often see valuation inflection.

Though Stellar is not specifically making vaccines, its KLH is a part of what could be blockbuster vaccines that are currently in proof-of-concept studies. If one of these vaccines is successful, that’s a reflection on Stellar. We believe the company stands to be the beneficiary of a successful vaccine from the point of view of KLH supply. Its valuation should flow hand-in-hand with the successes of its partners.

TLSR: Can you discuss some of the programs that Stellar is working on in conjunction with its partner companies?

JM: OBI is doing work in metastatic breast cancer. The whole idea of KLH is that it drives what I believe are antibody-biased responses. With KHL-based vaccines, you can also see significant T-cell responses. What OBI found in breast cancer patients with metastatic disease is that some patients developed significant antibody titers targeting globo H, which is the antigen it made the KLH vaccine with. There was a statistically significant improvement in progression-free survival, as well as overall survival.

This testing took place in China, and there are still a lot of things that have to happen in the U.S. and in Europe before investors really take note. I think people didn’t pay attention to this data, but to us it was a significant result. It is suggestive that a KLH-based immunotherapy could work in breast cancer, and we’re curious to see where OBI Pharma takes this. The benefit to Stellar is that it is going to keep supplying OBI’s KLH.

TLSR: What sets Stellar’s KLH apart from the competition?

JM: Stellar’s KLH is the only quality KLH that meets the standards for general manufacturing practices (GMP) grade. You can get lot-to-lot consistency such that you can actually make a vaccine that regulators could find suitable for approval. That’s the difference. If one of Stellar’s partner companies is successful, it would likely have to continue to use Stellar’s KLH. It has to use the same product it used to get through its clinical studies.

The competition, to our knowledge, can’t develop such a consistent KLH product. Stellar is the only company that has on-land aquaculture that houses and grows keyhole limpets, which is actually an animal. Thus, Stellar has a very defined population of keyohole limpets. The company is controlling the water environment, the nutrients the limpets are receiving. It is harvesting with very specific protocols, only at certain times a year, only a certain amount of KLH per animal.

“With KHL-based vaccines, you can also see significant T-cell responses.”
Other KLH manufacturers have to go to the Channel Islands in California, which is the only place keyhole limpets grow, to harvest the animals off the bottom of the ocean. Most people would say there’s inconsistency there. Even though the manufacturing process may be on par with what Stellar is doing, these companies have no idea what’s really happening in the ocean on a day-to-day basis. That’s the major difference between Stellar and any competitors in the KLH space.

TLSR: Does Stellar have an advantage in terms of cost because it is raising these animals in a facility as opposed to having to go out to the Channel Islands to harvest them?

JM: Stellar has a cost advantage in that, since the company raises the animals, it can manufacture in bulk. Having the manufacturing capability to meet kilograms and kilograms of demand (KLH protein) mitigates some costs associated with the aquaculture facility. . .supply and demand.

Overall, I think Stellar’s net margin is reasonable. We project the company’s cost of goods to be only about 35%, which a 65% margin—not as great as pharmaceutical margins at 80–90%, but better than where a biologic would be, like a checkpoint antibody or a chimeric antigen receptor (CAR) T-cell. We think Stellar has a viable commercial business.

Source – Streetwise / Tracy Salcedo

 

 

DISCLAIMER

 

Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

 

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

 

 

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

 

 

 

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.

 

 

 

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

 

 

 

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.

 

 

 

Please Note: We do NOT accept free trading or restricted securities as payment for our services.

 

 

 

SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

Stock market

 

Hot small cap stocks

 

small cap stock picks

 

Biotech stocks

 

FDA approval stocks

 

FDA calendar

 

Trade stocks

 

Become a day trader

 

Day trade stocks for a living

 

PDUFA date set

 

micro cap stocks

 

Best stocks 2016

 

Hottest small cap stocks

 

Best stock picks

 

Who to follow for stock picks

 

Apple news stock picks

 

Stock picks on apple news

New York, NY- June 23rd, 2016- (Apple News) –  Shares of Milestone Scientific Inc. (NYSE MKT: MLSS) are up 18% today at $2.55 per share after news the company was increasing its ownership of a subsidiary to 98.1%. Trading volume is at 146 thousand compared to its daily average trading rate of 27 thousand shares. Read the details of the MLSS transaction in this report. There is no cost or obligation to view the full report- https://broadstreetalerts.com/mlss/

 

 

About Broad Street Alerts

 

We make the connection between sophisticated investors and emerging growth small-cap companies. We are an issuer of reports written by chartered financial analysts (CFA’s) and or market experts who provide an assessment of the profiled company and have pledged to provide factual up to date information in their research. They include stocks traded in the NYSE and NASDAQ exchanges.

 

Safe Harbor Statement

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

 

Compliance Procedure

 

Content is researched, written and reviewed on a best-effort basis by a 3rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and research report. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

 

Contact: editor@BroadStreetAlerts.com

 

SOURCE: Broad Street Alerts

See feature article below: Milestone Scientific Inc. (NYSE MKT: MLSS)

Broad Street Alerts recent profiles and track record, 642% in verifiable potential gains for our members on 3 recent small cap alerts alone!

May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit over $4.15/share within 8 days for potential gains of 548% for our members.

May 23^rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.

May 26^th, 2016 (NASDAQ: CETX) opened at $2.00/share and hit $3.50/share within 10 days for potential gains of 74% for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report For: Milestone Scientific Inc. (NYSE MKT: MLSS)

Shares of MLSS are up 18% today at $2.55 per share after news the company was increasing its ownership of a subsidiary to 98.1%. Trading volume is at 146 thousand compared to its daily average trading rate of 27 thousand shares.

__________________

LIVINGSTON, NJ–(Marketwired – June 15, 2016) – Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that investors in the Company’s Epidural & Intra-Articular Subsidiary, Milestone Medical Inc. (“Milestone Medical”), have agreed to exchange their shares of Milestone Medical for shares of Milestone Scientific Inc. As a result, Milestone Scientific issued 583,747 new restricted shares to Milestone Medical investors, and now owns 98.1% of Milestone Medical. This share exchange follows an earlier transaction in April 2016, whereby Milestone Scientific increased its share ownership to 87%.

Under the current agreement, one of the largest financial institutions in Central Europe, with assets under management in excess of USD $5 billion, along with other investors in Milestone Medical, are exchanging their Milestone Medical shares for Milestone Scientific shares at a ratio of two Milestone Medical shares for one Milestone Scientific share.

Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, “With the completion of our clinical trials for the epidural instrument in the U.S., and other progress we have made, we are pleased to further increase Milestone Scientific’s ownership stake in Milestone Medical. The market potential for both our epidural and intra-articular instruments is significant, and we believe increasing our share ownership will benefit both Milestone Scientific and Milestone Medical shareholders. We would like to thank Graviton Capital for the role they played in the conversion and their continued support.”

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone’s computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

About Graviton Capital

Based in Poland, Graviton is a leading Central and Eastern European investment bank. Graviton’s focus is helping innovative North American companies broaden their shareholder base through long term relationships with Polish and other European institutional investors.

Source – Company Press Release

 

 

 

 

DISCLAIMER

 

Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

 

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

 

 

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

 

 

 

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.

 

 

 

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

 

 

 

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.

 

 

 

Please Note: We do NOT accept free trading or restricted securities as payment for our services.

 

 

 

SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.

 

Stock market

 

Hot small cap stocks

 

small cap stock picks

 

Biotech stocks

 

FDA approval stocks

 

FDA calendar

 

Trade stocks

 

Become a day trader

 

Day trade stocks for a living

 

PDUFA date set

 

micro cap stocks

 

Best stocks 2016

 

Hottest small cap stocks

 

Best stock picks

 

Who to follow for stock picks

 

Apple news stock picks

 

Stock picks on apple news